Editor's Correspondence |

Hypogonadism and Osteoporosis in Men—Reply

Gary M. Kiebzak, PhD; Garth A. Beinart, MD; Karen Perser, BA; Catherine G. Ambrose, PhD; Sherwin J. Siff, MD; Michael H. Heggeness, MD
Arch Intern Med. 2003;163(10):1237-1238. doi:10.1001/archinte.163.10.1237-a.
Text Size: A A A
Published online


In reply

We would like to respond to the thoughtful comments of Dr Mikhail. For the most part, we believe the apparent disagreement (ie, testosterone as a treatment for osteoporosis in men) expressed by Mikhail has more to do with semantics than substance. We agree that hypogonadal elderly men with osteoporosis likely will benefit from treatment with exogenous testosterone. However, in our study,1 in which we determined the number of men and women with hip fractures who were treated for osteoporosis, we tallied patients who were taking calcium and vitamin D only, patients taking a Food and Drug Administration–approved antiresorptive agent for the treatment and/or prevention of osteoporosis (namely, estrogen, calcitonin, raloxifene, alendronate, risedronate), and patients taking both calcium and vitamin D and an antiresorptive agent. Testosterone is not approved by the Food and Drug Administration for the treatment or prevention of osteoporosis. No studies have shown that testosterone decreases fracture risk in hypogonadal elderly men. There is no basis for a strategy of using testosterone solely for the purpose of treating low bone mineral density in men. Thus, we justifiably did not include testosterone as an "osteoporosis treatment."

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles

Users' Guides to the Medical Literature

Users' Guides to the Medical Literature
A trial of sodium fluoride as secondary prevention against osteoporosis in postmenopausal women...